Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 17.1% on Wednesday . The stock traded as low as C$0.28 and last traded at C$0.32. 684,632 shares were traded during trading, an increase of 2% from the average session volume of 673,865 shares. The stock had previously closed at C$0.38.
Hemostemix Trading Down 17.1 %
The stock has a market capitalization of C$27.44 million, a P/E ratio of -15.75 and a beta of 0.20. The company has a fifty day simple moving average of C$0.15 and a two-hundred day simple moving average of C$0.10.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Investing In Automotive Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- The Significance of Brokerage Rankings in Stock Selection
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
